Huayuan Securities released a research report on April 25 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) the company is one of the leading domestic blood products companies with strong long-term growth certainty; 2) the blood products industry has strong resource attributes. Asset restructuring has been obvious in recent years, and it is expected that industry concentration will continue to increase. (Mainichi Keizai Shimbun)
华源证券4月25日发布研报称，给予派林生物（000403.SZ）买入评级。评级理由主要包括：1）公司是国内血制品头部企业之一，长期成长确定性强；2）血制品行业资源属性强，近年来资产重组明显，预计行业集中度将持续提升。（每日经济新闻）
Huayuan Securities released a research report on April 25 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) the company is one of the leading domestic blood products companies with strong long
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.